このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Home-Based Transitional Cardiac Rehabilitation Trial With a Partially Randomized Patient Preference Design

2026年11月12日 更新者:Yu-Shan Lin、Cheng-Hsin General Hospital

A Confirmatory Non-Inferiority Trial of Home-Based Transitional Cardiac Rehabilitation, With a Partially Randomized Patient Preference (PRPP) Design, Informed by Pilot Data

This is a prospective, single-center, non-inferiority trial comparing a hospital-to-home transitional cardiac rehabilitation model with standard hospital-based cardiac rehabilitation in low-risk patients after cardiac surgery in Taiwan. Because patients' post-discharge scheduling constraints and treatment preferences make full randomization difficult to sustain in practice, the trial uses a Partially Randomized Patient Preference (PRPP) design: patients without a strong preference are randomized 1:1 to the two programs and form the randomized core cohort used for the primary confirmatory analysis, while patients with a clear, pre-specified preference are assigned accordingly and followed descriptively as a preference cohort. The primary hypothesis is that the hospital-to-home model is non-inferior to hospital-based rehabilitation in improving peak oxygen uptake (Peak VO2) after 8 weeks. A pre-specified key secondary hypothesis, based on an exploratory finding from the investigators' completed pilot study, is that the hospital-to-home model results in significantly lower 6-month outpatient medical costs. The trial does not include a no-treatment control arm; assay sensitivity is instead supported by the extensive existing evidence base for cardiac rehabilitation versus no treatment and for home-based versus center-based cardiac rehabilitation equivalence, following the constancy assumption described in ICH E10.

調査の概要

詳細な説明

Rationale: A completed single-center pilot study (Cheng Hsin General Hospital institutional research grant, FY112) enrolled 30 patients (15 per arm, 4 withdrawals) and found a directional, exploratory signal of non-inferiority for the hospital-to-home model on Peak VO2, and a significant reduction in 6-month outpatient medical costs favoring the hospital-to-home arm. However, the pilot's original sample size was calculated using a two-tailed paired-sample t-test, which is not the correct method for a parallel-group non-inferiority design, so its non-inferiority conclusion was exploratory only. This confirmatory trial re-estimates the required sample size using the pilot's observed variance (ANCOVA-adjusted residual SD = 2.71 ml/min/kg) and the correct non-inferiority formula, and adopts a Partially Randomized Patient Preference (PRPP) design to address the real-world constraint that many post-discharge patients have strong scheduling or logistical preferences between an in-hospital and a home-based program.

Design: Prospective, parallel-group, non-inferiority trial with PRPP allocation. Patients without a strong preference (operationally defined as absence of a specific, identifiable scheduling, transportation, or technology-related constraint) are randomized 1:1 in permuted blocks to the hospital-to-home transitional model or hospital-based cardiac rehabilitation, forming the randomized core cohort (planned n=29 per arm, 58 total) that constitutes the intention-to-treat population for the primary confirmatory non-inferiority analysis. Patients with a clear, investigator-confirmed preference are assigned to their preferred program and followed as a preference cohort (planned n≈40) analyzed descriptively; their baseline characteristics are compared with the randomized core cohort to characterize potential selection effects, but they do not contribute to the primary confirmatory hypothesis test. Assuming approximately 60% of screened patients accept randomization (a planning assumption to be re-examined at the interim analysis), the overall enrollment target is 98 participants.

No-treatment control arm: The trial does not include a usual-care/no-rehabilitation control arm. The investigators considered a three-arm design to formally establish assay sensitivity but did not adopt it because (a) the effect of cardiac rehabilitation versus no treatment is already well established by a large existing evidence base, including the Cochrane meta-analyses cited in the 2026 ESC Guidelines on Cardiac Rehabilitation (85 RCTs / 23,430 patients in coronary artery disease; 60 RCTs / 8,728 patients in heart failure); (b) the equivalence of home-based and center-based cardiac rehabilitation has similarly been established at the meta-analytic level by the 2023 Cochrane review (24 RCTs, 3,046 patients); (c) adding a no-treatment arm would raise the enrollment target from 58 to approximately 134 in the randomized core cohort, which is not feasible for a single center; and (d) published hybrid cardiac rehabilitation non-inferiority/equivalence trials (iATTEND, HYCARET, and a French single-center trial) have similarly used two active comparator arms without a no-treatment control. This design relies on the ICH E10 constancy assumption rather than re-establishing assay sensitivity with concurrent trial data.

Outcome hierarchy: Given the number of secondary endpoints assessed in the pilot without multiplicity correction, this trial pre-specifies a hierarchical (fixed-sequence) gatekeeping procedure to control the family-wise type I error rate: Gate 1 tests the primary non-inferiority hypothesis on Peak VO2; Gate 2, tested only if Gate 1 is met, formally tests the pre-specified key secondary hypothesis on 6-month outpatient medical cost; Gate 3 outcomes (quality of life/QALY, medication adherence, secondary CPET indices, pulmonary function) are analyzed and reported descriptively as pre-specified but exploratory, without formal multiplicity control, and are entered under Other Pre-specified Outcome Measures below rather than Secondary Outcome Measures.

Missing data: Primary and secondary efficacy outcomes with missing values will be handled by multiple imputation (MICE, ≥20 imputations, pooled per Rubin's rules), with complete-case analysis as a sensitivity analysis. An interim analysis is planned at 50% enrollment for safety monitoring by an independent Data Safety Monitoring Board (DSMB); no interim efficacy testing is performed, so no alpha-spending adjustment is required. The interim analysis will also re-examine the actual randomization-acceptance rate against the 60% planning assumption and adjust the recruitment period or target if needed.

研究の種類

介入

入学 (推定)

151

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:SHENG-CHI Lo, BS. PT.
  • 電話番号:+886-02-28264400 EXT 3459
  • メール:fy10940619@gmail.com

研究連絡先のバックアップ

  • 名前:Yu-Shan Lin, PT, MSc, CRFC
  • 電話番号:+886-02-28264400 EXT 3459
  • メール:itsyushanlin@gmail.com

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

20年~75年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria

  • Post-cardiac-surgery patients at the study hospital
  • Age 20-75 years
  • Low cardiovascular risk (AHA 2013 exercise training risk stratification, Class B), clinically stable
  • Able to self-monitor exercise intensity

Exclusion Criteria

  • High risk of sudden cardiac death
  • Sustained atrial fibrillation or non-sustained ventricular tachycardia within the preceding 6 months
  • Implanted cardioverter-defibrillator (ICD)
  • Unable to independently operate the communication/exercise software or devices required for the home-based program
  • Declines to undergo study testing

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
実験的:Hybrid cardiac rehabilitation (Experimental)

Description:Weeks 1-2: 4 supervised hospital sessions (twice weekly). End of week 2: risk reassessment (AACVPR algorithm; patients with high-risk features do not transition to home) and teaching of home resistance exercise. Weeks 3-8: home aerobic exercise at least 3 times per week and elastic-band resistance exercise at least 2 times per week; remote 30-second ECG at rest daily and after each exercise session; exercise log; weekly telephone call; two standardized text messages per week; return visit at week 4. Participants choose this arm.

Hybrid cardiac rehabilitation (hospital-to-home transition):as in Arm 1; aerobic intensity is based on the anaerobic-threshold heart rate from baseline CPET when available, otherwise moderate intensity (RPE 12-13); resistance exercise uses elastic bands (4-8 exercises, RPE 11-13) with sternal precautions; intensity at home does not exceed the hospital sessions; upper-limb movements at home are added only after individual confirmation by the therapist.

アクティブコンパレータ:Standard center-based cardiac rehabilitation (Active Comparator)

Description:Two supervised hospital sessions per week for 8 weeks (16 sessions), plus weekly verbal encouragement to exercise on their own and a home exercise log. Exercise prescription follows the hospital routine and is made in the same way as in the hybrid arm. Participants choose this arm.

Standard center-based cardiac rehabilitation:as in Arm 2.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change in Peak Oxygen Uptake (VO2peak) Measured by Cardiopulmonary Exercise Testing
時間枠:Baseline (Week 0) and Week 8

Description:VO2peak (mL/kg/min) is the highest 30-second average oxygen uptake during a symptom-limited bicycle ramp cardiopulmonary exercise test with breath-by-breath gas analysis. Change = week 8 value minus week 0 value. Non-inferiority margin: 1.5 mL/kg/min.

Baseline (Week 0) and Week 8

二次結果の測定

結果測定
メジャーの説明
時間枠
Peak Oxygen Uptake (VO2peak) Measured by Cardiopulmonary Exercise Testing at 6 Months After Week 8
時間枠:6 months after week 8

Description:Key secondary outcome. VO2peak (mL/kg/min) measured as for the primary outcome. Tested in a fixed sequence only if non-inferiority is shown for the primary outcome.

6 months after week 8
Number of Attended Supervised Exercise Sessions, From Hospital Attendance Records
時間枠:Weeks 1-8.

Description:Count of supervised hospital sessions attended per participant (prescribed: 4 in the hybrid arm, 16 in the standard arm).

Weeks 1-8.
Number of Home Exercise Sessions per Week, Recorded in the Home Exercise Log
時間枠:Weeks 1-8.

Description:Mean number of self-reported home exercise sessions per week (aerobic and resistance), from the participant's home exercise log.

Weeks 1-8.
Number of Participants Who Attend at Least 80% of Prescribed Supervised Sessions, From Hospital Attendance Records
時間枠:Week 8.

Description:Participants attending at least 80% of the supervised sessions prescribed for their arm.

Week 8.
Health Utility Measured by the EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) Index Score Using the Taiwan Value Set
時間枠:Baseline (week 0), week 8, and 6 months after week 8

Description:The EQ-5D-5L describes health in 5 dimensions with 5 levels each; responses are converted to an index score with the Taiwan value set (Lin et al., PLoS One 2018). Index range -1.0259 to 1; 1 = full health; higher scores indicate better health.

Baseline (week 0), week 8, and 6 months after week 8
Self-Rated Health Measured by the EuroQol Visual Analogue Scale (EQ VAS)
時間枠:Baseline (week 0), week 8, and 6 months after week 8

Description:EQ VAS ranges from 0 (worst imaginable health) to 100 (best imaginable health); higher scores indicate better health.

Baseline (week 0), week 8, and 6 months after week 8
Six-Minute Walk Distance Measured by the 6-Minute Walk Test
時間枠:Baseline (week 0) and week 8

Description:Distance walked in 6 minutes (meters).

Baseline (week 0) and week 8
Patient Satisfaction Measured by the Client Satisfaction Questionnaire-8 (CSQ-8) Total Score
時間枠:Week 8 and 6 months after week 8

Description:8 items each scored 1 to 4; total score ranges from 8 to 32; higher scores indicate greater satisfaction.

Week 8 and 6 months after week 8

その他の成果指標

結果測定
メジャーの説明
時間枠
Number of Outpatient Visits, Excluding Cardiac Rehabilitation Sessions, From Hospital Records and National Health Insurance Data
時間枠:From week 8 through 6 months after week 8

Count of outpatient visits per participant; cardiac rehabilitation sessions are excluded.

From week 8 through 6 months after week 8
Number of Emergency Department Visits, From Hospital Records and National Health Insurance Data
時間枠:From week 8 through 6 months after week 8

Count of emergency department visits per participant.

From week 8 through 6 months after week 8
Number of Hospital Admissions, From Hospital Records and National Health Insurance Data
時間枠:From week 8 through 6 months after week 8

Count of hospital admissions per participant.

From week 8 through 6 months after week 8
Total Length of Hospital Stay, From Hospital Records and National Health Insurance Data
時間枠:From week 8 through 6 months after week 8

Total inpatient days per participant.

From week 8 through 6 months after week 8
Outpatient and Emergency Department Medical Expenditure, Excluding Cardiac Rehabilitation-Related Charges
時間枠:From week 8 through 6 months after week 8

Total outpatient and emergency department medical expenditure per participant in New Taiwan Dollars (NTD), from hospital billing records and National Health Insurance data.

From week 8 through 6 months after week 8
Inpatient Medical Expenditure
時間枠:From week 8 through 6 months after week 8

Total inpatient medical expenditure per participant in NTD, from hospital billing records and National Health Insurance data.

From week 8 through 6 months after week 8
Participant Time Spent on the Rehabilitation Program, Measured by a Study-Specific Time-Cost Questionnaire
時間枠:Weeks 1-8

Total hours spent on travel to and from the hospital and on rehabilitation sessions (supervised and home-based) per participant.

Weeks 1-8
Medication Adherence Measured by the 8-Item Morisky Medication Adherence Scale (MMAS-8)
時間枠:Baseline (week 0), week 8, and 6 months after week 8

Total score ranges from 0 to 8; higher scores indicate better adherence.

Baseline (week 0), week 8, and 6 months after week 8
Number of Participants Reporting Current Tobacco Use, Assessed by Self-Report Questionnaire
時間枠:Baseline (week 0), week 8, and 6 months after week 8

Participants reporting any tobacco use in the past 30 days

Baseline (week 0), week 8, and 6 months after week 8
Muscle Mass Measured by Bioelectrical Impedance Analysis (ACCUNIQ BC720)
時間枠:Baseline (week 0) and week 8

Muscle mass in kilograms.

Baseline (week 0) and week 8
Body Fat Percentage Measured by Bioelectrical Impedance Analysis (ACCUNIQ BC720)
時間枠:Baseline (week 0) and week 8

Body fat as a percentage of body weight.

Baseline (week 0) and week 8
Forced Vital Capacity (FVC) Measured by Spirometry
時間枠:Baseline (week 0), week 8, and 6 months after week 8

FVC in liters.

Baseline (week 0), week 8, and 6 months after week 8
Forced Expiratory Volume in 1 Second (FEV1) Measured by Spirometry
時間枠:Baseline (week 0), week 8, and 6 months after week 8

FEV1 in liters.

Baseline (week 0), week 8, and 6 months after week 8
Ratio of FEV1 to FVC (FEV1/FVC) Measured by Spirometry
時間枠:Baseline (week 0), week 8, and 6 months after week 8

FEV1/FVC expressed as a percentage.

Baseline (week 0), week 8, and 6 months after week 8
Minute Ventilation to Carbon Dioxide Output Slope (VE/VCO2 Slope) Measured by Cardiopulmonary Exercise Testing
時間枠:Baseline (week 0), week 8, and 6 months after week 8

Slope of the linear relationship between minute ventilation and carbon dioxide output during exercise (unitless); lower values indicate better ventilatory efficiency.

Baseline (week 0), week 8, and 6 months after week 8
Oxygen Uptake Efficiency Slope (OUES) Measured by Cardiopulmonary Exercise Testing
時間枠:Baseline (week 0), week 8, and 6 months after week 8

Slope of oxygen uptake (mL/min) against the log10 of minute ventilation (L/min); higher values indicate better efficiency.

Baseline (week 0), week 8, and 6 months after week 8
Oxygen Uptake at the First Ventilatory Threshold (VO2 at VT1) Measured by Cardiopulmonary Exercise Testing
時間枠:Baseline (week 0), week 8, and 6 months after week 8

VO2 at the first ventilatory threshold in mL/kg/min.

Baseline (week 0), week 8, and 6 months after week 8
Heart Rate Recovery at 1 Minute (HRR1) After Cardiopulmonary Exercise Testing
時間枠:Baseline (week 0), week 8, and 6 months after week 8

Peak heart rate minus heart rate 1 minute into recovery, in beats per minute; higher values indicate better recovery.

Baseline (week 0), week 8, and 6 months after week 8
Heart Disease-Specific Quality of Life Measured by the MacNew Heart Disease Health-Related Quality of Life Questionnaire Global Score
時間枠:Baseline (week 0), week 8, and 6 months after week 8

27 items; global score ranges from 1 to 7; higher scores indicate better health-related quality of life.

Baseline (week 0), week 8, and 6 months after week 8
Depressive Symptoms Measured by the Patient Health Questionnaire-9 (PHQ-9) Total Score
時間枠:Baseline (week 0), week 8, and 6 months after week 8

Total score ranges from 0 to 27; higher scores indicate more severe depressive symptoms.

Baseline (week 0), week 8, and 6 months after week 8
Anxiety Symptoms Measured by the Generalized Anxiety Disorder 7-Item Scale (GAD-7) Total Score
時間枠:Baseline (week 0), week 8, and 6 months after week 8

Total score ranges from 0 to 21; higher scores indicate more severe anxiety symptoms.

Baseline (week 0), week 8, and 6 months after week 8
Number of Participants With Adverse Events During Exercise Testing, Supervised Training or Home Exercise
時間枠:From baseline (week 0) through 6 months after week 8 (approximately 8 months)

Adverse events include cardiovascular events (e.g., arrhythmia requiring intervention, angina, syncope, abnormal blood pressure response, myocardial infarction, stroke, death), musculoskeletal injury and sternal wound complications, recorded by therapists, the remote ECG review, the exercise log and weekly telephone calls.

From baseline (week 0) through 6 months after week 8 (approximately 8 months)
Number of Participants Who Discontinue the Intervention
時間枠:Weeks 1-8

Participants who stop the assigned intervention for any reason; reasons are reported.

Weeks 1-8

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Yu-Shan Lin, PT, MSc, CRFC、Chief Physical Therapist, Cheng Hsin General Hospital

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2027年1月1日

一次修了 (推定)

2028年2月28日

研究の完了 (推定)

2028年7月31日

試験登録日

最初に提出

2026年11月3日

QC基準を満たした最初の提出物

2026年11月12日

最初の投稿 (実際)

2026年11月18日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月18日

QC基準を満たした最後の更新が送信されました

2026年11月12日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する